Biopharma investment into the formulation, delivery, and commercialization of intranasal therapies is at an all-time high, and there has never been such an opportunistic time to pursue nasal delivery. Alongside the market projection for intranasal therapies being forecasted to reach $21.2 billion by 2032, 2025 breakthroughs included Atzumi being approved for migraine treatment, and Eli Lilly’s Baqsimi now being applied to severe Hypoglycemia. The clock is ticking for biopharma to master their formulations first time for systemic and CNS targeting, streamline preclinical and clinical trial success, and achieve regulatory approval to drive products to market.
In uniting large pharma, expanding mid-sized biotech, and startup innovators, you will achieve technical excellence for your formulation and delivery that will future-proof commercialization, and meet potential partners who will co-develop your intranasal therapies. Adopt groundbreaking insights on pre-clinical and clinical intranasal study data for different delivery methods to obtain practical takeaways that will transform the trajectory of your intranasal success. Join biopharma in igniting a new era of innovation where intranasal delivery holds the power to unparalleled medical benefits.
To know more visit: https://ter.li/eqlf0s